Similar Papers

Paper Title
Journal
Date
Author
Carfilzomib 56mg/m2 Twice-Weekly in Combination with Dexamethasone and Daratumumab (KdD) Versus Daratumumab in Combination with 8 Cycles of Bortezomib and Dexamethasone (DVd); A Matching-Adjusted Indirect Treatment Comparison
Katja Weisel ... Shaji K Kumar
Blood | VOL. 136
Katja Weisel, et. al.Katja Weisel ... Shaji K Kumar
05 Nov 2020
Impact of Modified Thalidomide Dosing in Bortezomib/Thalidomide/Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible: A Matching-Adjusted Indirect Comparison
Pieter Sonneveld ... Philippe Moreau
Blood | VOL. 134
Pieter Sonneveld, et. al.Pieter Sonneveld ... Philippe Moreau
13 Nov 2019
Cost per Responder Analysis to Assess the Value of CAR-T Therapy for Relapsed or Refractory Multiple Myeloma
Thomas Martin ... Sundar Jagannath
Blood | VOL. 138
Thomas Martin, et. al.Thomas Martin ... Sundar Jagannath
05 Nov 2021
926P - Erdafitinib (erda) versus available therapies in advanced urothelial cancer: A matching adjusted indirect comparison
Y Loriot ... A O Siefker-Radtke
Annals of Oncology | VOL. 30
Y Loriot, et. al.Y Loriot ... A O Siefker-Radtke
01 Oct 2019
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Reactive oxygen species regulate early development of the intestinal macrophage-microbiome interface.
Zohreh Mansoori Moghadam ... Philipp Henneke
Blood | VOL. -
Zohreh Mansoori Moghadam, et. al.Zohreh Mansoori Moghadam ... Philipp Henneke
03 Feb 2025
Deficiency of T follicular helper cell Tet3 DNA demethylation inhibits pathogenic IgG2c class switching and chronic GVHD.
Michael C Zaiken ... Bruce R Blazar
Blood | VOL. -
Michael C Zaiken, et. al.Michael C Zaiken ... Bruce R Blazar
03 Feb 2025
How I approach pharmacological thromboprophylaxis in children.
Anthony A Sochet ... Neil A Goldenberg
Blood | VOL. -
Anthony A Sochet, et. al.Anthony A Sochet ... Neil A Goldenberg
03 Feb 2025
Woyach JA, Burbano GP, Ruppert AS, etal. Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL. Blood. 2024;143(16):1616-1627.
-
Blood | VOL. 145
--
30 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.